Πρωτεύουσες καρτέλες
Ο κατάλογος των δημοσιεύσεων είναι ενδεικτικός και μπορεί να μην περιλαμβάνει το σύνολο των δημοσιεύσεων.
Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas..
Endocr Relat Cancer. 15(3), 693-700.
(2008).
High density lipoprotein cholesterol and statin trials..
Curr Med Chem. 15(22), 2265-70.
(2008).
Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes..
Acta Diabetol. 45(1), 23-30.
(2008).
Omega-3 fatty acids: how can they be used in secondary prevention?.
Curr Atheroscler Rep. 10(6), 510-7.
(2008).
Preventing macrovascular complications of diabetes: where do we stand with glycemic control?.
Expert Opin Investig Drugs. 17(12), 1777-9.
(2008).
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study..
Nephrol Dial Transplant. 22(1), 118-27.
(2007).
Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism..
Nephrol Dial Transplant. 22(1), 293.
(2007).
The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?.
Expert Opin Ther Targets. 11(2), 191-205.
(2007).
Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?.
Curr Pharm Des. 13(2), 229-39.
(2007).
Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels..
Curr Drug Targets. 8(3), 483-8.
(2007).
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?.
Expert Opin Pharmacother. 8(5), 529-35.
(2007).
Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors?.
Ann Allergy Asthma Immunol. 98(5), 502.
(2007).
Serum uric acid as an independent predictor of early death after acute stroke..
Circ J. 71(7), 1120-7.
(2007).
Persistent effect of zoledronic acid in Paget's disease..
Clin Exp Rheumatol. 25(3), 464-6.
(2007).
Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients..
Lipids. 42(11), 999-1009.
(2007).
Endothelial function, arterial stiffness and lipid lowering drugs..
Expert Opin Ther Targets. 11(9), 1143-60.
(2007).
Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients..
Open Cardiovasc Med J. 1, 8-14.
(2007).
Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?.
Expert Opin Pharmacother. 8(14), 2267-77.
(2007).
Should atenolol still be recommended as first-line therapy for primary hypertension?.
Hellenic J Cardiol. 47(5), 298-307.
(2006).
Dry cough as first manifestation of giant-cell arteritis..
J Am Geriatr Soc. 54(12), 1957-8.
(2006).
Angioedema may not be a class side-effect of the angiotensin-converting-enzyme inhibitors..
QJM. 99(3), 197-8.
(2006).
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study..
Curr Med Res Opin. 22(5), 873-83.
(2006).
Targeting vascular risk in patients with metabolic syndrome but without diabetes..
Metabolism. 54(8), 1065-74.
(2005).